Bridging lipid metabolism and innate host defense.

Claudia dos Santos, John C Marshall

Registry-linked trialAbstract readComment

In one paragraph

Article in Science translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03634293 (PCSK9 Inhibitor), which is not on this map. Cited by 7 papers.

0numbers the graph read from it

0cells of the map it votes in

7citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03634293 phase2 / phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

PCSK9 Inhibitor: a New Tool to Fight Septic Shock

TypeinterventionalSponsorWolfson Medical CenterRan2019 to 2021Enrolled712ConditionsSepsis, Septic ShockArmsAlirocumab Injectable Product, Saline Solution

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

Proprotein Convertase Subtilisin Kexin 9 Inhibitor in Severe Sepsis and Septic Shock Patients in a Phase II Prospective Cohort Study-Preliminary Results.Infectious disease reports · 2024
Article
Anti-inflammatory effect of ApoE23 onOpen medicine (Warsaw, Poland) · 2023
Article
PCSK9 induces a pro-inflammatory response in macrophages.Scientific reports · 2018
Article
The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.Global cardiology science & practice · 2017
Review
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Cardiovascular research · 2016
Review
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.The Journal of biological chemistry · 2016
Article
IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study.Cardiology journal
Article

4 · The record

Corrections and comments

Comment on
PCSK9 is a critical regulator of the innate immune response and septic shock outcome.2014

5 · Who and what money

Authors and funding

2 authors.

Claudia dos SantosDepartment of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario M5B 1W8, Canada. Department of Critical Care Medicine and the Keenan Research Centre for Biomedical Science of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario M5B 1W8, Canada.

John C MarshallDepartment of Critical Care Medicine and the Keenan Research Centre for Biomedical Science of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario M5B 1W8, Canada. Department of Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario M5B 1W8, Canada. marshallj@smh.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Host- and pathogen-derived lipids share clearance mechanisms that pinpoint PCSK9 as a plausible target for the treatment of some patients with sepsis (Walley et al., this issue).

Indexed as

Immunity, InnateAnimalsHumansMaleProprotein ConvertasesSerine EndopeptidasesShock, SepticProprotein ConvertasesSerine Endopeptidases

Identifiers

PMID25320231

DOI10.1126/scitranslmed.3010501

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

NCT03634293ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.